STOCK TITAN

Quince Therapeutics (QNCX) S-3 Filings

QNCX NASDAQ

Ticker history: QNCX became IRLA (IRulya Therapeutics Inc.) on .

Here are the S-3 shelf registrations from Quince Therapeutics, Inc. (QNCX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow QNCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNCX filings page.

Rhea-AI Summary

Quince Therapeutics, Inc. filed Amendment No. 1 to its Form S-3 registration statement primarily to add a legal opinion as Exhibit 5.1, leaving the substantive terms of the existing shelf registration unchanged. The amendment includes an updated Part II with an itemized estimate of offering-related expenses totaling $498,600, including a $38,600 SEC registration fee, legal, accounting, printing, and transfer agent costs, which will be borne by the company rather than the selling stockholders.

The company restates its Delaware-law–based indemnification and liability-limitation protections for directors and officers, and confirms standard SEC shelf undertakings regarding post-effective amendments, incorporation by reference, and treatment of indemnification for Securities Act liabilities. The filing is executed on behalf of Quince by Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., with a power of attorney authorizing designated officers to sign future amendments.

Rhea-AI Summary

Quince Therapeutics, Inc. is registering up to 15,470,099 shares of Common Stock for resale by existing selling stockholders, consisting of Acquisition Shares, Series C preferred conversion shares and warrant conversion shares from its Orphai Therapeutics acquisition and a 2026 private placement.

The company will not receive proceeds from stockholder resales, but may receive cash if Acquisition and Financing Warrants are exercised. The May 2026 private placement issued 144,200.633 Series C Non-Voting Convertible Preferred shares at $797.50 each for approximately $115 million, each preferred share automatically convertible into 52 Common shares upon stockholder approvals and subject to ownership caps.

Quince recently acquired Orphai, making inhaled rapamycin candidate LAM-001 its lead asset, with ongoing Phase 2 trials in PH-ILD and BOS and a planned SAPH trial. Two reverse stock splits in April and June 2026 created a cumulative 1-for-200 adjustment, reducing common shares outstanding to 278,627 as of June 29, 2026.